Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Multihance: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Multihance - General Information

In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, Multihance shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, Multihance primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Multihance does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars).

 

Pharmacology of Multihance

Gadobenate dimeglumine shares the pharmacokinetic properties of the ECF contrast agent gadopentetate dimeglumine; however, gadobenate differs in that is also selectively taken-up by hepatocytes and excreted via the bile (up to 5% of dose). The elimination half-life of gadobenate dimeglumine is approximately 1 hour. It is not metabolized.

 

Additional information about Multihance

Multihance Indication

For magnetic resonance imaging (MRI) of the central nervous system in adults to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues.

Mechanism Of Action
Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, Multihance shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, Multihance primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Multihance does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars).
Generic Name
Gadobenate Dimeglumine
Synonyms
Gadobenic acid
Drug Category
Contrast Media
Drug Type
Small Molecule; Approved
Other Brand Names containing Gadobenate Dimeglumine
Gd-BOPTA; Gd-BOPTA/Dimeg; Multihance; Multihance Multipack;
Protein Binding
Plasma protein binding is low, weak, and transient.
Biotransformation
Not metabolized
Half Life
1 hour
Dosage Forms of Multihance
Solution Intravenous
Chemical IUPAC Name
2-[carboxymethyl-[2-[2-[carboxymethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl]amino]-3-phenylmethoxypropanoate; gadolinium(+3) cation; (2R,3R,4R,5S)-6-methylaminohexane-1,2,3,4,5-pentol
Chemical Formula
C36H62GdN5O21
Organisms Affected
Humans and other mammals